XOMA to Present at Two Upcoming Investor Conferences

BERKELEY, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA, a leader in the discovery and development of therapeutic antibodies, announced today members of its executive team will present at two upcoming investor conferences. The details are as follows:

• Jefferies Autumn 2015 Global Healthcare Conference London on Thursday, November 19 at 3:20p.m. GMT (7:20 a.m. PT)
• 27^th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1 at 10:00 a.m. ET (7:00a.m. PT)

Live audio webcasts of the presentations can be accessed through the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. Archived versions of the webcast will be available via replay for 30 days following the presentations.

About XOMA Corporation

XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from the Company's expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of 6 endocrine assets, each of which have the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major effect on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358. Additionally, XOMA is developing gevokizumab (IL-1 beta modulating antibody) in an ongoing Phase 3 program enrolling patients with pyoderma gangrenosum, a rare ulcerative skin condition. For more information, visit www.xoma.com.